Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables - Net: 2012-2025

Historic Receivables - Net for Ascendis Pharma A (ASND) over the last 11 years, with Sep 2025 value amounting to $157.5 million.

  • Ascendis Pharma A's Receivables - Net rose 333.33% to $157.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.5 million, marking a year-over-year increase of 333.33%. This contributed to the annual value of $180.0 million for FY2024, which is 366.27% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Receivables - Net is $157.5 million, which was up 25.98% from $125.0 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Receivables - Net registered a high of $177.7 million during Q4 2024, and its lowest value of $72,374 during Q1 2021.
  • Over the past 3 years, Ascendis Pharma A's median Receivables - Net value was $44.6 million (recorded in 2024), while the average stood at $70.1 million.
  • In the last 5 years, Ascendis Pharma A's Receivables - Net tumbled by 80.23% in 2021 and then surged by 8,906.72% in 2022.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Receivables - Net stood at $2.5 million in 2021, then soared by 382.81% to $12.2 million in 2022, then skyrocketed by 217.65% to $38.6 million in 2023, then surged by 360.35% to $177.7 million in 2024, then surged by 333.33% to $157.5 million in 2025.
  • Its Receivables - Net was $157.5 million in Q3 2025, compared to $125.0 million in Q2 2025 and $70.1 million in Q1 2025.